Trial · NCT03577899
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)
NCT03577899, Phase 3, Terminated, Chengdu Kanghong Biotech Co., Ltd.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1). Trials, record NCT03577899. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03577899
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)
- NCT number
- NCT03577899
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 1,157 participants, actual
- Lead sponsor
- Chengdu Kanghong Biotech Co., Ltd.
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection
- First posted
- 2018-07-05
- Last updated
- 2021-06-24
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean change from baseline in best corrected visual acuity (BCVA) at Week 36 in the study eye | Baseline to Week 36 | BCVA was assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) method |
| Secondary | Proportion of subjects maintaining vision (i.e., losing <15 ETDRS BCVA letters) from baseline to Week 36 | Baseline to Week 36 | To assess proportion of subjects maintaining vision (i.e., losing \<15 ETDRS BCVA letters) from baseline to Week 36 |
| Secondary | Proportion of subjects gaining ≥15 ETDRS BCVA letters from baseline to Week 36 | Baseline to Week 36 | To assess proportion of subjects gaining ≥15 ETDRS BCVA letters from baseline to Week 36 |
| Secondary | Mean change from baseline in central retinal thickness (µm) by spectral domain optical coherence tomography (SD-OCT) at Week 36 | Baseline and Week 36 | To assess mean change from baseline in central retinal thickness (µm) by spectral |
| Secondary | Proportion of subjects maintaining vision (i.e. losing <15 ETDRS BCVA letters) from baseline to Week 48 | Baseline to Week 48 | To assess proportion of subjects maintaining vision (i.e. losing \<15 ETDRS BCVA letters) from baseline to Week 48 |
| Secondary | Mean change from baseline in ETDRS BCVA letter score at Week 96 | Baseline and Week 96 | To assess mean change from baseline in ETDRS BCVA letter score at Week 96 |
| Secondary | Number of participants with adverse events as measure of safety and tolerability | Baseline to Week 96 | To assess the number of participants with adverse events as measure of safety and tolerability |
| Secondary | Blood concentration of conbercept doses conducted in a subgroup of subjects, when feasible | Baseline to Week 96 | To assess the blood concentration of conbercept doses conducted in a subgroup of subjects, when feasible |
| Secondary | Half-life (t1/2) of conbercept doses conducted in a subgroup of subjects, when feasible | Baseline to Week 96 | To assess half-life (t1/2) of conbercept doses conducted in a subgroup of subjects, when feasible |
| Secondary | Presence of anti-drug antibody of conbercept doses conducted in a subgroup of subjects, when feasible | Baseline to Week 96 | To assess the presence of anti-drug antibody of conbercept doses conducted in a subgroup of subjects, when feasible |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03577899
GET https://conductscience.org/api/trials/v1/NCT03577899/registered